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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: Infections caused by methicillin-resistant Staphylococcus aureus (MRSA)
continue to be a problem for clinicians worldwide. The objective of this study was to deter-
mine the changes in antibiograms of MRSA and their genotypic characteristics.
Methods: The antibiograms of 162 MRSA isolates (52 from 2003 and 110 from 2008) from a ter-
tiary hospital were analyzed by antimicrobial susceptibility tests, the Panton-Valentine leuko-
cidin (PVL) and staphylococcal cassette chromosome mec (SCCmec) types were determined by
polymerase chain reaction, and genetic relatedness by pulsed-field gel electrophoresis (PFGE)
and multilocus sequence typing (MLST).
Results: All the isolates were sensitive to vancomycin. Resistance to ciprofloxacin, clindamy-
cin, erythromycin, and gentamicin remained high throughout the study period, although a
small decrease was observed in 2008 for ciprofloxacin (96% to 90%) and gentamicin (90% to
83%). Similarly, a slight decrease in resistance toward fusidic acid (10% to 9%), linezolid (2%
to 1%), rifampicin (8% to 4%), and teicoplanin (4% to 0%) was observed between 2003 and
2008. In contrast, there was a significant increase (p < 0.05) in resistance rates toward
trimethoprim-sulfamethoxazole, netilmicin, and tetracycline between 2003 and 2008.y Division, Institute of Biological Science, Faculty of Science, University of Malaya, 50603 Kuala
y (K.L. Thong).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Methicillin-resistant Staphylococcus aureus strains 225Ninety-six percent of the isolates from both 2003 and 2008 were multidrug resistant. Three
SCCmec types (SCCmec type III, 90%; SCCmec type IV, 9%; SCCmec V, 1%) were observed.
SCCmec type IV (n Z 15) and pvl gene (n Z 3) were detected in 2008 isolates but not in
2003 isolates. Most of the SCCmec type IV isolates (12 of 15) belonged to sequence type 22
(ST22) and were resistant to erythromycin and ciprofloxacin, with 11 being multidrug resistant.
Most of the isolates were genetically related (F > 0.8) as determined by PFGE. Some isolates
from 6 years apart shared similar PFGE profiles, indicating the persistence of a particular
genotype. Five STs (ST239, ST772, ST22, ST6, and ST1178) were identified among the 2008
isolates but only one ST (ST239) was observed in 2003 isolates.
Conclusion: Vancomycin remains the most active agent in vitro against S. aureus infection
followed by linezolid and teicoplanin. The prevalence of resistance to fluoroquinolones, ami-
noglycosides (netilmicin), and tetracyclines had increased over the years. The Malaysian
multidrug-resistant MRSA isolates were mostly SCCmec type III and ST239, although SCCmec
type IV: ST22 is gaining importance. There was a correlation between resistotypes and PFGE
profiles.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is an
important bacterial pathogen associated with community
(CA) and health care (HA) infections in Malaysia and
worldwide. In a local study, the MRSA infection rate in a
tertiary hospital was reported at 10.0 among 1000 hospital
admissions.1 The incidence of MRSA hospital infections in
Japan was between 0.7 and 0.8 per 100 admissions from
1999 to 2003.2 The rate of MRSA infections among hospi-
talized patients in the Asia-Pacific region was 45.9%.3
The prevalence of MRSA in Malaysian hospitals has
increased from 17% in 19864 to 44.1% in 2007.5 An increase
of 62% in MRSA was reported in the United States.6 Because
most MRSA is also resistant to many commonly used anti-
biotics, this has raised concern over the limited choice of
antimicrobial agents for the treatment of life-threatening
cases. This could lead to a prolonged hospital stay and in-
crease the cost of care.7,8 A death rate of 34% within 30
days was observed among patients with MRSA infections as
compared to 27% in patients with methicillin-sensitive
Staphylococcus aureus (MSSA).9
MRSA has evolved from methicillin-susceptible S. aureus
via acquisition of mobile genetic elements called staphy-
lococcal cassette chromosomemec (SCCmec) which has two
essential components, the ccr gene complex (ccr) and the
mec gene complex (mec).10,11 Previous studies in Malaysia
have shown that HA-MRSA strains are associated with
SCCmec type III whereas CA-MRSA is associated with
SCCmec type IV and SCCmec type V.5,12,13 There are no
reports on the presence of other SCCmec types in Malaysia.
Panton-Valentine leukocidin (PVL) positive S. aureus is
normally associated with CA-MRSA infections such as skin
and mucous membrane infections, necrotizing pneumonia,
urinary tract infections, and endocarditis.13,14
Rapid and discriminative subtyping methods are essen-
tial for determining the epidemiology of pathogenic strains
and are useful in the design of rational pathogen control
methods. Several methods are available and these
include pulsed-field gel electrophoresis (PFGE), multilocussequence typing (MLST), direct repeat unit (DRU) typing,
spa typing, and other polymerase chain reaction (PCR)-
associated typing methods.15 MLST has been shown to be
useful in global epidemiologic studies of S. aureus.
Ghaznavi-Rad et al14 reported that more than 90% of MRSA
infections in a tertiary hospital (HKL) in Malaysia belonged
to MLST type ST239, whereas Ahmad et al5 reported that
most of the CA-MRSA reported in Malaysia belonged to MLST
type ST30.
The changing epidemiology of MRSA is an important
public health concern as infections caused by CA-MRSA are
increasing.16,17 The objective of this study was to deter-
mine the changes in the antimicrobial susceptibility profiles
of MRSA in a Malaysian tertiary teaching hospital between
the years 2003 and 2008 and their genotypic characteristics
as determined by PFGE, MLST, SCCmec, and PVL typing.Materials and methods
Bacterial isolates
One hundred sixty-two nonduplicate MRSA isolates obtained
from 158 patients and four healthcare workers (52 from
2003 and 110 from 2008) from the University Malaya Medical
Centre (UMMC), Kuala Lumpur, Malaysia, were analyzed.
UMMC is a 980-bed referral teaching hospital in Malaysia,
which has orthopedic, pediatric, medical, surgical, ob-
stetrics and gynecology, and psychiatry wards, and general
intensive care units and neurology intensive care units. All
MRSA isolates that could be revived from 2003 and 2008
stock cultures were included for analysis.
The isolates were identified as MRSA by standard
methods in UMMC and were checked for purity before
analysis. All the isolates were cultured in Luria-Bertani
broth and stored in cryovials with 50% glycerol (Invitrogen,
Grand Island, NY, USA) at e20C and e85C.
Ninety-nine percent (161 of 162) of MRSA isolates were
HA-MRSA. HA-MRSA refers to cases with positive culture
obtained 48 hours after admission to the hospital, whereas
226 K.T. Lim et al.CA-MRSA refers to cases with no association with healthcare
setting.18 The organisms were isolated from nasal swabs
(n Z 37; 23%), tissue (n Z 13; 8%), wound swabs (n Z 28;
17%), urine (nZ 6; 4%), pus (nZ 12; 7%), body fluids (nZ 24;
15%), sputum (n Z 20; 12%), nasopharyngeal secretion
(nZ 7; 4%), catheter tip (nZ 3; 2%), bone (nZ 4; 3%), blood
(nZ 7; 4%), and chest tube “drainage” (nZ 1; 1%).
Antimicrobial susceptibility testing
The antimicrobial susceptibility of S. aureus isolates to 13
antimicrobial agents [vancomycin (30 mg), oxacillin (1 mg),
ciprofloxacin (5 mg), tetracycline (30 mg), erythromycin
(15 mg), fusidic acid (75 mg), netilmicin (30 mg), teicoplanin
(30 mg), gentamicin (10 mg), linezolid (30 mg), rifampicin
(5 mg), trimethoprim-sulfamethoxazole (75 mg), and clinda-
mycin (2 mg) (Oxoid Ltd, Basingstoke, Hampshire, UK)] was
determined by the disk diffusion method according to Clin-
ical and Laboratory Standard Institutes guidelines.19 The
minimum inhibitory concentration (MIC) for vancomycin was
confirmed using Etest (Ab Biodisk, Solna, Sweden). S. aureus
isolate ATCC25923 was used as the quality control strain for
the antimicrobial susceptibility test as recommended by the
Clinical and Laboratory Standards Institute.19
The D-zone test method, which is used for the detection
of inducible clindamycin resistance (known as inducible
macrolides, lincosamides, and streptograminB, i-MLSB) and
constitutive clindamycin resistance (known as constitutive
macrolides, lincosamides, and streptograminB [cMLSB]) was
performed on all erythromycin-resistant isolates according
to established protocols20,21 and the results were inter-
preted as described previously.20,21
PCR detection of pvl gene and SCCmec types
Genomic deoxyribonucleic acid (DNA) from MRSA was
extracted by using the Wizard Genomic DNA purification kit
(Promega, Madison, WI, USA). An aliquot (approximately
5 ng) was used as a DNA template for PCR analysis. Primers
for the detection of pvl and SCCmec types were as previously
described by Lina et al22 and Milheirico et al23 (Operon Bio-
technologies GmBH, Cologne, Germany) were used.
Specific primers 4a1, 4a2, 4b1, 4b2, 4c1, 4c2, 4d1, and
4d2 as described by Hisata et al24 and Okuma et al25 were
used for further subgrouping the SCCmec IV isolates. Eight
positive-control MRSA isolates, NCTC10442, N315, 85/2082,
JCSC4744, JCSC2172, JCSC4469, JCSC4788 and WI5 were
used for SCCmec types I, II, III, IVa, IVb, IVc, IVd, and V,
respectively (courtesy of Dr. Teruyo Ito, Japan). All PCR
experiments were repeated once to confirm their
reproducibility.
PFGE and MLST
PFGE was performed according to published work.13 The
chromosomal DNA was digested with 10 U SmaI followed by
separation on CHEF DRIII (Bio-Rad, Hercules, CA, USA) in 0.
5 Tris-borate-ethylenediaminetetraacetic acid (EDTA) at
14C for 22 hours with pulse times of 5e60 seconds. Gels
were photographed under ultraviolet light after staining
with ethidium bromide (0.5 mg/mL).Cluster analyses of PFGE profiles were analyzed with
BioNumerics Version 6.0 (Applied Maths, Kortrijk, Belgium)
based on the unweighted pair group method with arith-
metic averages (UPGMA) with a position tolerance of 0.15.
All PFGE profiles were assigned an arbitrary designation,
and differences were defined by the Dice coefficient of
similarity, F.
MLSTwas conducted on all SCCmec type IV, PVL positive,
and representative isolates of each predominant PFGE type
as described earlier by Enright et al.26 The sequence types
(STs) were assigned via the S. aureus MLST database (www.
mlst.net).Statistical analysis
A statistical software package STATISTICA (Version 8.0,
StatSoft, Inc, Tulsa, OK, USA; http://www.statsoft.com/
products/) was used for data analysis. Comparison of
certain variables was determined by the Fisher exact test.
A p value <0.05 (two-tailed) was taken as the level of sig-
nificance for the Fisher exact test.Results
Antimicrobial susceptibility profiles
All the isolates were sensitive to vancomycin. Linezolid,
teicoplanin, and rifampicin resistance remained low
(1e5%). In contrast, resistance to ciprofloxacin, erythro-
mycin, clindamycin, and gentamicin remained high
throughout the study period. A summary of the antimicro-
bial resistance rates for MRSA isolates is shown in Table 1.
There was a significant increase in the rates of resistance to
trimethoprim-sulfamethoxazole (p < 0.01), netilmicin
(p Z 0.01), and tetracycline (p < 0.01) for 2008 isolates
compared with the 2003 isolates. There was no significant
difference in the resistance rates in 2003 and 2008 for the
following antimicrobial agents: ciprofloxacin (96% in 2003
and 90% in 2008), gentamicin (90% in 2003 and 83% in 2008),
rifampicin (8% in 2003 and 4% in 2008), fusidic acid (10% in
2003 and 9% in 2008), teicoplanin (4% in 2003 and 0% in
2008), clindamycin (94% in 2003 and 96% in 2008), and
linezolid (2% in 2003 and 1% in 2008) (p > 0.05). The
resistance rates for erythromycin remained the same.
Most (n Z 109, 99%) of the 2008 isolates were sensitive
to teicoplanin except for one nasopharyngeal secretion
isolate, which showed intermediate susceptibility. Ninety-
nine percent (n Z 148) of the ciprofloxacin-resistant
isolates were also resistant to erythromycin. Similarly,
99% (n Z 137) of gentamicin-resistant isolates were also
resistant to erythromycin except for a nasal swab isolate
MRSA0805-10 from a patient in the orthopedic ward.
A total of 106 isolates (96%) from 2008 and 50 (96%)
isolates from 2003 were multidrug resistant (MDR) (resistant
to more than three classes of antimicrobial agents). Three
isolates (MRSA0308-23, MRSA0805-15, and MRSA0812-33)
were resistant to more than seven classes of antimicrobial
agents, including penicillins, macrolides, aminoglycosides,
lincosamides, fluoroquinolones, tetracyclines, folate
pathway inhibitors, and fusidic acid.
Methicillin-resistant Staphylococcus aureus strains 227Based on the D-zone test, 96% (150 of 156) and 3% (4 of
156) of the erythromycin-resistant isolates showed induc-
ible clindamycin resistance and constitutive clindamycin
resistance, respectively. Two erythromycin-resistant iso-
lates did not have any flattening of the clindamycin zone
adjacent to the erythromycin disk.
pvl Gene and SCCmec types
pvl Gene was detected in three isolates from 2008
(Table 1). No pvl gene was detected in 2003 isolates. Three
SCCmec types were observed: SCCmec type III (90%,
nZ 146), SCCmec type IV (9%, nZ 15), and SCCmec type V
(1%, n Z 1) (Table 1). Thirteen SCCmec type IV isolates
were further subtyped as SCCmec type IVa. A significant
difference in the numbers of SCCmec type III and SCCmec
type IV between 2003 and 2008 was observed.
One hundred and forty-one SCCmec type III isolates (50
from 2003 and 91 from 2008) were MDR. There was no sig-
nificant difference in the percentage of isolates with MDR
status among SCCmec type III in 2003 and 2008 (96% vs. 97%,
pZ 1.0). Most (93%, nZ 14) SCCmec type IV isolates were
MDR and also resistant to ciprofloxacin.
Genotypes of MRSA based on PFGE and MLST
SmaI-digested genomic DNA of the 162 MRSA isolates
resulted in 84 distinct pulsed-field profiles (PFPs)
comprising 10e18 restriction fragments (F Z 0.57e1.00).
Based on the interpretation proposed by Tenover et al,27
these 84 PFPs were further grouped into 63 PFGE types
where closely related isolates with a similarity of more than
97% (1e2 band difference) was considered as a unique PFGE
type (Fig. 1). Most of the isolates were genetically related
(F > 0.8). Thirty-five isolates shared the same PFGE type
even though they were cultured from different sources and
occasions (Fig. 1). Some isolates from 6 years apart sharedTable 1 Resistance rates, PVL, and SCCmec types of Malaysian















SCCmec type III 52 (100)
SCCmec type IV 0 (0)
SCCmec type V 0 (0)
pvl 0 (0)similar PFGE profiles, indicating the persistence of a
particular genotype.
MLST was performed on all SCCmec type IV (n Z 15),
SCCmec type V (n Z 1), and representative isolates for
each predominant PFGE type (n Z 18). This identified five
STs (ST239, ST772, ST22, ST6, and ST1178). MLST type
ST239 was observed from both 2003 (n Z 9) and 2008
(n Z 9) isolates, whereas new MLST types ST772 (n Z 1),
ST22 (n Z 12), ST6 (n Z 1), and ST1178 (n Z 2) were
identified among the 2008 isolates. All 12 ST22 isolates
carried SCCmec type IV (Table 2).
Combined analysis
A dendrogram based on combined PFPs and resistotypes is
shown in Fig. 2. All 162 MRSA isolates were differentiated
into 110 combined subtypes. Some isolates (i.e., MRSA0807-
19, MRSA0808-19, MRSA0305-10, and MRSA0312-17) shared
the same combined subtypes even though they were
cultured independently from different time periods and
sources. Based on 70% similarity, five clusters were
observed. Cluster 1 consists of 127 isolates; Clusters 2 and 3
consist of three isolates; Cluster 4 consists of 12 isolates;
and Cluster 5 consists of seven isolates. Nine isolates were
not grouped into any of the clusters.
Fifty-nine isolates within Cluster 1 were clonally related
(shared more than 80% similarity) although they were from
different sources and years. These isolates were also
resistant to gentamicin, erythromycin, and clindamycin and
98% of them were of SCCmec type III. Some isolates that
were indistinguishable by PFGE were further differentiated
in the combined analysis as they had different resistotypes.
For example, MRSA0801-26, MRSA0805-22, MRSA0812-37,
MRSA0309-10, MRSA0809-25, MRSA0806-33, MRSA0810-9,
MRSA0807-19, MRSA0808-19, MRSA0305-10, and MRSA0312-
17 were further differentiated by their resistotypes
although they shared similar PFGE profiles.MRSA isolates in 2003 and 2008
2008, n Z 110 (%) Total (%) p
99 (90) 149 (92) 0.23
106 (96) 155 (96) 0.68
106 (96) 156 (96) 1.00
10 (9) 15 (9) 1.00
91 (83) 138 (85) 0.24
1 (1) 2 (1) 0.54
55 (50) 69 (43) 0.01
4 (4) 8 (5) 0.27
0 (0) 2 (1) 0.11
71 (65) 81 (50) < 0.01
80 (73) 99 (61) < 0.01
0 (0) 0 (0) 1.00
94 (85) 146 (90) < 0.01
15 (14) 15 (9) < 0.01
1 (1) 1 (1) 1.00
3 (3) 3 (2) 0.55
Figure 1. Dendrogram of PFGE SmaI-digested chromosomal DNA profiles of MRSA. PFGE Z pulsed-field gel electrophoresis.
228 K.T. Lim et al.Based on PFGE analysis, the only SCCmec type V isolate
was clonally related (shared 81.8% similarity) with one
SCCmec type III (MRSA0807-13). However, they only shared
79.8% in the combined analysis as these two isolates had
unique resistotypes.
Among the 15 SCCmec type IV isolates, one was grouped
in Cluster 1, 12 in Cluster 4, and two isolates were not
grouped in any cluster. The 12 isolates within Cluster 4
belonged to MLST type ST22, with seven of them sharing the
same resistotype (Fig. 2, Table 2).
Two teicoplanin-resistant isolates (MRSA0311-23 and
MRSA0312-35) shared 78.2% similarity and were grouped in
Cluster 1 (Fig. 2). Both were SCCmec type III but haddifferent resistotypes. MRSA0311-23 was resistant to
erythromycin, gentamicin, ciprofloxacin, oxacillin, and
trimethoprim-sulfamethoxazole, whereas MRSA0312-35 was
resistant to mupirocin, tetracycline, oxacillin, and fusidic
acid.Discussion
Infections caused by MRSA continue to be a problem in
Malaysian hospitals. Although several studies have docu-
mented the antimicrobial resistance trends of MRSA in
other countries,6,7 reports comparing resistance trends and
Table 2 Resistotypes, PFGE, and MLST types of SCCmec type IV and V isolates
Isolates Resistotypes MLST PFGE type
MRSA0801-21 CIP, ERY, LZD, CN, SXT, DA, NET ST22 51
MRSA0803-28 CIP, ERY, SXT, DA ST22 28
MRSA0804-1 CIP, ERY, SXT, DA ST22 54
MRSA0805-9 CIP, ERY, SXT, DA ST22 55
MRSA0806-21 CIP, ERY, SXT, DA ST22 56
MRSA0810-10 CIP, ERY, FD ST22 50
MRSA0810-17 CIP, ERY, FD, DA ST22 49
MRSA0810-22 CIP, ERY, SXT, DA ST22 51
MRSA0811-22 CIP, ERY, SXT, DA ST22 53
MRSA0811-30 CIP, TE, ERY, SXT, DA ST22 52
MRSA0812-1 CIP, ERY, SXT, DA ST22 54
MRSA0812-23 CIP, ERY, TE, CN, SXT, DA, NET ST22 54
MRSA0805-10 CIP, CN, SXT ST1178 39
MRSA0805-1 ERY, FD, SXT ST1178 3
MRSA0806-11 Alla ST6 1
MRSA0812-36 CIP, ERY, CN, SXT ST772 46
a Sensitive to all the antimicrobial agents tested.
CIPZ ciprofloxacin; CNZ gentamicin; DAZ clindamycin; ERYZ erythromycin; FDZ fusidic acid; LZDZ linezolid; MLSTZ multilocus
sequence typing; NET Z netilmicin; PFGE Z pulsed-field gel electrophoresis; SXT Z trimethoprim-sulfamethoxazole;
TE Z tetracycline.
Methicillin-resistant Staphylococcus aureus strains 229their genetic characteristics between two periods of time
in Malaysia are scarce. This report shows detailed antimi-
crobial resistance trends and the genetic characteristic of
MRSA isolated in a tertiary hospital in 2003 and 2008.
In this study, tetracycline-resistant MRSA had signifi-
cantly increased over a 6-year period (p < 0.01), possibly
because of an increased usage of tetracycline or doxycy-
cline in the hospital. Thong et al13 reported tetracycline
resistance rate of MRSA at 32% in the year 2003. The
increase in the tetracycline resistant rate has also been
reported in another Malaysian hospital.12 There was a sig-
nificant increase in resistance rates to trimethoprim-
sulfamethoxazole from 2003 to 2008. This was probably
also due to an increased usage of trimethoprim-
sulfamethoxazole in the hospital (unpublished hospital re-
cords). Similar high resistance rates were reported by Neela
et al12 (75%) and Thong et al13 (73%). There was a sharp
increase in netilmicin resistance rates between 2003 and
2008. Thong et al13 reported an increase in netilmicin
resistance rate from 16% in 2003 to 41% in 2004. However,
netilmicin resistance rates (50%) noted in this study were
lower when compared to the 68.7% rate from 2006 to 2007
reported by Neela et al.12
In addition, the rates of resistance to erythromycin re-
ported in this study remained high (96%) in 2003 and 2008.
This is concordant with previously reported erythromycin
resistance rates of 81.2e96.0%.5,12,13 Both inducible and
constitutive MLSB phenotypes were observed among
erythromycin-resistant isolates, with most (96%) showing
the i-MLSB phenotype. The prevalence of i-MLSB isolates
(92%) was much higher when compared with the 63%
reported in Korea (in 2004).28 The resistance rates of clin-
damycin had increased slightly from 94% (in 2003) to 96% (in
2008) over 6 years. This was much higher than that previ-
ously reported in Malaysia by Ahmad et al5 (0%), Al-Talib
et al1 (6%), and Neela et al12 (0%).Even though SCCmec type II MRSA isolates are predomi-
nant in Korea and Japan,10,11 they are absent in Malaysia.
The predominant SCCmec in Malaysia is SCCmec type III
(90%), and this SCCmec type III is also common in hospitals
in Singapore, Thailand, Taiwan, and Indonesia.11,29 All 15
SCCmec type IV MRSA isolates (9%) were HA-MRSA (unpub-
lished hospital records), although SCCmec type IV MRSA
isolates were mostly associated with CA-MRSA.5 SCCmec
type IV HA-MRSA has been previously reported in
Denmark.30 In addition, all SCCmec type IV isolates were
susceptible to rifampicin, mupirocin, teicoplanin, and
vancomycin. This is in agreement with a previous report by
Ahmad et al5 that SCCmec type IV isolates are susceptible
to four or more non-b-lactam antibiotics. Similarly, D’Souza
et al31 also reported that 83% of their SCCmec type IV iso-
lates from India were susceptible to many classes of anti-
microbials agents. Two of 12 ST22 SCCmec type IV MRSA
isolates reported here were resistant to gentamicin. This
differs from the report of Ahmad et al5 (Malaysia) and
Conceic¸a˜o et al32 (Atlantic Azores islands), where the ST22
isolates were sensitive to gentamicin and tetracycline.
One SCCmec type IV isolate (MRSA0805-10) shared
similar PFPs with two SCCmec type III isolates (MRSA0808-17
and MRSA0811-11) but had different resistotypes. Similarly,
some SCCmec type III and SCCmec type IV isolates shared
more than 90% similarity by PFGE and resistotypes. This
suggests that these isolates might have acquired a different
mec and ccr gene complex, resulting in differences in
SCCmec types even though they shared a similar PFGE type.
Most (80%) of the SCCmec type IV MRSA isolates belonged
to MLST type ST22, followed by ST1178 (13.3%) and ST6
(6.67%). The presence of ST22, ST1178, and multisensitive
ST6 in SCCmec type IV MRSA isolates from the same hospital
had been previously reported by Sam et al.33 The presence
of a clone with SCCmec type IV and ST22 genotype has also
been reported in Italy, Australia, India, and Iran.31,34e36
AFigure 2. Computed dendrogram derived from combined data analysis of PFGE and resistotypes for 2003 and 2008 MRSA isolates.
The dotted vertical line indicates 70% similarity level. (A) MRSA0807-19, MRSA0808-19, MRSA0305-10, MRSA0312-17. (B) MRSA0804-1.
(C) MRSA0805-9. CIPZ ciprofloxacin; CNZ gentamicin; DAZ clindamycin; EZ erythromycin; FDZ fusidic acid; LZDZ linezolid;
NET Z netilmicin; RD Z rifampicin; SXT Z trimethoprim-sulfamethoxazole; TE Z tetracycline; TEC Z teicoplanin;
VAZ vancomycin.
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Figure 2. (continued).
Methicillin-resistant Staphylococcus aureus strains 231The SCCmec IV: ST22 from the Atlantic Azores islands
belonged to SCCmec type IVh (Conceic¸a˜o et al32), whereas
all the SCCmec type IV: ST22 in the current study were
SCCmec type IVa. Even though ST30 (SCCmec type IV) and
ST1 are known as pandemic MRSA clones,37 they are absent
in this study.
The high ciprofloxacin resistant rates among SCCmec
type IV isolates in this hospital might be because of the high
usage of antibiotics in the hospital (unpublished data). Higherythromycin- and trimethoprim-sulfamethoxazole resis-
tance rates were also observed among SCCmec type IV
isolates, and similar observations had been previously re-
ported in a hospital in Southern Iran by Japoni et al.36
Coombs et al34 reported the presence of SCCmec type IV,
MLST type ST22 isolates with erythromycin and ciprofloxa-
cin resistance among MRSA isolated from western Australia.
The only SCCmec type V isolate (MRSA0812-36) found in
this study was CA-MRSA, PVL negative, ST772 and MDR.
232 K.T. Lim et al.SCCmec type V was first reported in CA-MRSA from nasal
swabs of healthy local university students.38 Ahmad et al5
and Otter and French39 proposed gentamicin and cipro-
floxacin, respectively, as phenotypic markers for CA-MRSA.
However, the only CA-MRSA isolates in this study were
resistant to both the antimicrobial agents. Therefore, both
antimicrobial agents might not be suitable to be used as the
phenotypic marker of CA-MRSA in this tertiary hospital.
MLST type ST239 remained as the predominant clone in this
tertiary hospital. Similarly, more than 90% of MRSA isolates
from another tertiary hospital in Malaysia belonged to this
pandemic clone.15
Combined analysis based on PFPs and resistotypes
showed that most of the MRSA isolates were clonally
related even though they were cultured at different times.
This suggests that several clones of MRSA isolates were
circulating in this tertiary hospital during the study period.
Some other 2003 and 2008 isolates also shared similar
combined subtypes and this further implies persistence of
certain clones within the hospital environment. The pres-
ence of three indistinguishable clinical isolates, which were
cultured during the same month (July) but from different
wards, further supports the notion of the circulation of a
particular clone in the hospital.
Most of the isolates resistant to tetracycline (90% in both
2003 and 2008) and trimethoprim-sulfamethoxazole (68% in
2003 and 79% in 2008) in 2003 and 2008 belong to Cluster 1.
The tetracycline and trimethoprim-sulfamethoxazole iso-
lates might be a part of the persistent clone in the hospital
environment.
In conclusion, correlation between PFGE profiles and
resistotypes was observed. Isolates with indistinguishable
PFGE profiles often have similar antibiotic susceptibility
patterns even though there are variations in certain anti-
biograms in distinct clones of MRSA. The antibiotic resis-
tance rates had increased over the years and the
persistence of MDR isolates remains a problem. Although
MRSA with SCCmec type III with MLST type ST239 is pre-
dominant in Malaysia, SCCmec type IV with MLST type ST22
is gaining prominence. The MDR MRSA clinical isolates from
UMMC were mostly genetically related, suggesting that few
predominant clones of the species are involved in infection.Acknowledgments
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